Subscribe

Prostate Cancer

FDA Approves First Prostate-Specific Membrane Antigen–Targeted PET Imaging Drug for Prostate Cancer
FDA Approvals, News & Updates, Prostate Cancer
December 2020, Vol 11, No 6
On December 1, 2020, the FDA approved Gallium 68 PSMA-11 (Ga 68 PSMA-11; University of California), the first drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer. Ga 68 PSMA-11 is indicated for men with suspected metastatic prostate cancer that may be curable by surgery or by radiation, and for suspected recurrent prostate cancer based on elevated serum prostate-specific antigen (PSA) levels.
Read Article
Oral Relugolix Equals Standard ADT, Slashes Cardiac Events in Patients with Advanced Prostate Cancer
By Phoebe Starr
Prostate Cancer
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Oral relugolix given daily is superior to standard androgen-­deprivation therapy (ADT) with leuprolide (Lupron) in men with advanced prostate cancer, according to the results of the phase 3 HERO study, which were reported at the ASCO 2020 virtual annual meeting and published online before the meeting.
Read Article
Cabozantinib plus Atezolizumab Combination Shows Meaningful Activity in Metastatic Prostate Cancer
By Phoebe Starr
Prostate Cancer
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
The combination of cabozantinib (Cabometyx), a kinase inhibitor, and atezolizumab (Tecentriq), a PD-L1 inhibitor, achieved clinically meaningful activity in patients with metastatic castration-resistant prostate cancer (CRPC), including those with high-risk clinical features, according to the results of the phase 1b COSMIC-021 trial presented at the ASCO 2020 virtual annual meeting.
Read Article
Early Phase 2 Data Promising for Lutetium-177 PSMA-617 in Metastatic Prostate Cancer
By Phoebe Starr
Prostate Cancer
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Early results from the phase 2 TheraP clinical trial show that the targeted radiation therapy Lutetium-177 PSMA-617 (Lu-PSMA) significantly improved prostate-specific antigen (PSA) response compared with standard cabazitaxel in men with metastatic castration-resistant prostate cancer (CRPC) that progressed after docetaxel therapy.
Read Article
Immune Checkpoint Inhibitor Does Not Improve Outcomes in Metastatic Prostate Cancer
By Phoebe Starr
Prostate Cancer
June 2020, Vol 11, No 3
No improvement in survival or in any key secondary end point was observed when the checkpoint inhibitor atezolizumab (Tecentriq) was added to enzalutamide (Xtandi) for the treatment of metastatic castration-resistant prostate cancer (CRPC) in the phase 3 IMbassador250 trial. The study results were presented at the 2020 American Association for Cancer Research virtual annual meeting.
Read Article
Androgen-Deprivation Therapy Seldom Used with Radiation in Localized Prostate Cancer
By Wayne Kuznar
Prostate Cancer
June 2020, Vol 11, No 3
San Francisco, CA—Today, patients who receive stereotactic body radiation therapy (SBRT) for intermediate- or high-risk localized prostate cancer are not receiving concurrent androgen-deprivation therapy (ADT), despite national guideline recommendations that support the concurrent use of ADT with radiation therapy.
Read Article
Lynparza Approved for Metastatic Prostate Cancer with HRR Mutation
FDA Approvals, News & Updates, Prostate Cancer
Web Exclusives
On May 19, 2020, the FDA approved a new indication for olaparib (Lynparza; AstraZeneca), a PARP inhibitor, for the treatment of men with metastatic castration-resistant prostate cancer and deleterious or suspected deleterious germline or somatic HRR mutation, as determined by an FDA-approved test, whose disease progressed after enzalutamide (Xtandi) or abiraterone acetate (Zytiga) therapy. Olaparib is the first FDA-approved PARP inhibitor for prostate cancer.
Read Article
PSMA-PET Scanning Wave of the Future in Prostate Cancer
By Phoebe Starr
Prostate Cancer
April 2020, Vol 11, No 2

San Francisco, CA—Positron emission tomography (PET) scanning targeted to detect prostate-specific membrane antigen (PSMA) is poised to overtake conventional imaging, according to presentations at the 2020 Genitourinary Cancers Symposium.

Read Article
Cabozantinib–Atezolizumab Combination Shows Activity in Difficult-to-Treat Prostate Cancer
By Wayne Kuznar
Prostate Cancer
April 2020, Vol 11, No 2

San Francisco, CA—Combining cabozantinib (Cabometyx) with atezolizumab (Tecentriq) induced responses in 32% of patients with metastatic castration- resistant prostate cancer (CRPC) who had soft-tissue progression after previous novel hormonal therapy.

Read Article

Page 2 of 8

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
© Amplity Health. All Rights Reserved. Privacy Policy.